Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Margin data on file, last reported at 77.94% in Q1 2026.

• Gross Margin for Q1 2026 came in at 77.94%, down 120.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 83.52% (down 149.0% YoY), and the FY2025 annual result was 83.8%, down 245.0% from the prior year.
• Gross Margin slipped to 77.94% in Q1 2026 per RARE's latest filing, from 85.84% in the prior quarter.
• Over five years, Gross Margin peaked at 94.85% in Q4 2022 and troughed at 77.94% in Q1 2026.
• A 5-year average of 87.18% and a median of 87.8% in 2023 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2025: Gross Margin slumped 565 bps in 2022, then surged 66 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 94.85% in 2022, then fell by 4 bps to 90.69% in 2023, then slipped by 1 bps to 89.57% in 2024, then fell by 4 bps to 85.84% in 2025, then fell by 9 bps to 77.94% in 2026.
• Business Quant data shows RARE's Gross Margin at 77.94% in Q1 2026, 85.84% in Q4 2025, and 82.5% in Q3 2025.